Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ConocoPhillips (COP) vs Quest Diagnostics Inc (DGX) Price & Performance

ConocoPhillipsTrade
Quest Diagnostics IncTrade

Price performance (Past 24H)

Key statistics

ConocoPhillips vs Quest Diagnostics Inc — how do they compare? ConocoPhillips trades at $133.54 (market cap $161.21B), while Quest Diagnostics Inc trades at $230.72 (market cap $25.48B). The key difference: ConocoPhillips is far larger — about 6.3× Quest Diagnostics Inc's market cap, and ConocoPhillips pays the higher dividend (2.5%). Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Quest Diagnostics Inc for 56 Days on average.

COPDGX
Market Cap
$161.21B$25.48B
Volume
6,058,403941,866
Sector
EnergyHealth
52-Week High
$141.22$247.45
52-Week Low
$85.66$173.49
Typical Hold Time
79 Days56 Days
Enterprise Value
$176.81B$31.23B
Dividend Yield
2.5%1.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ConocoPhillips

ConocoPhillips (COP) trades at $129.84, up 0.38% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a net income margin of 14.65% and a P/E of 17.17, while recent earnings beat expectations in Q1 and Q2 2026. A 20-year LNG supply deal with Venture Global, announced October 1, 2026, highlights strategic growth initiatives.

The outlook is positive, supported by a 75% analyst buy rating and a consensus price target of $154.75, implying 19% upside. Risks include geopolitical exposure in the Middle East and oil price volatility, but robust cash flow and shareholder returns provide stability for investors.

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.

The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

COP
1% Buy99% Sell
Avg holding period · 79 Days
DGX

No sentiment data available yet.

Top news

Latest headlines on both assets

About ConocoPhillips

ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.

Read more on COP →

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX →